Market Pulse

Latest company updates, ordered by publication date.

Thompson Thrift

Thompson Thrift Completes St. Augustine Multifamily Redevelopment

Event summary

  • Thompson Thrift has completed Terrassa, a 324-unit Class A multifamily community in St. Augustine, Florida.
  • The project redevelops the former St. Augustine Outlets property, located off I-95.
  • Residents began moving in September 2025, with a ribbon-cutting event held on March 2, 2026.
  • Equity for the project was provided by Thompson Thrift 2024 Multifamily Development, LP.
  • Thompson Thrift donated to S.A.F.E. Pet Rescue and waived adoption fees at the ribbon-cutting event.

The big picture

Thompson Thrift's redevelopment of the St. Augustine Outlets demonstrates a continued focus on capitalizing on Florida's population growth and demand for high-end multifamily housing. The project’s design and amenities cater to a demographic seeking a blend of convenience and lifestyle, a trend increasingly prevalent in coastal markets. With over $7.1 billion invested, Thompson Thrift’s strategy emphasizes long-term community partnerships and a vertically integrated approach to real estate development.

What we're watching

Market Saturation
The success of Terrassa will hinge on its ability to maintain occupancy rates in a competitive coastal Florida market, given the ongoing influx of new multifamily developments.
Capital Sourcing
Thompson Thrift’s reliance on dedicated development LPs like 2024 Multifamily Development, LP, suggests a potential constraint on future project scale and geographic expansion.
Amenity Appeal
The extensive amenity package (pickleball court, dog spa, social hub) may become a necessity to retain residents, and Thompson Thrift will need to monitor evolving resident preferences to justify the investment.
UroGen Pharma Ltd.

UroGen's ZUSDURI Launch Gains Momentum as Reimbursement Barriers Fall

Event summary

  • UroGen's ZUSDURI, a treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, achieved $15.8 million in net sales during 2025.
  • A permanent Healthcare Common Procedure Coding System (J Code) for ZUSDURI became effective January 1, 2026, streamlining reimbursement.
  • UroGen refinanced its term loan with Pharmakon Advisors, securing $200 million in additional non-dilutive capital.
  • JELMYTO sales reached $94 million in 2025, representing 7% year-over-year underlying demand growth.
  • Clinical trial data for UGN-103, a next-generation treatment, showed a 77.8% complete response rate, paving the way for an NDA submission in 2H 2026.

The big picture

UroGen's progress with ZUSDURI highlights the increasing importance of targeted therapies in oncology, particularly for cancers with limited treatment options. The permanent J Code is a significant de-risking event, but the company's reliance on a single product and pipeline progression creates concentrated execution risk. The refinancing, while providing capital, also increases financial leverage and underscores the need for continued revenue growth.

What we're watching

Adoption Rate
The sustained acceleration of ZUSDURI adoption post-J Code will be critical to validating the initial sales projections and justifying the company's valuation.
Pipeline Progression
The success of the NDA submission for UGN-103 and subsequent FDA approval will determine if UroGen can maintain its competitive advantage in the bladder cancer treatment space.
Debt Burden
UroGen's ability to manage the increased debt load from the Pharmakon refinancing, particularly given the lack of full-year ZUSDURI sales guidance, will be a key indicator of financial stability.
Lifeward Ltd.

Lifeward Partners with AbilityLab to Streamline Exoskeleton Access

Event summary

  • Lifeward is collaborating with Shirley Ryan AbilityLab to offer dedicated clinic days for evaluation and trial of the ReWalk Personal Exoskeleton, starting in Q2 2026.
  • The clinics aim to accelerate adoption of the ReWalk exoskeleton for individuals with spinal cord injury (SCI).
  • Shirley Ryan AbilityLab will provide clinical evaluation, training, and support throughout the process.
  • This marks Lifeward’s first collaboration with a nationally recognized rehabilitation research hospital.

The big picture

Lifeward's collaboration with Shirley Ryan AbilityLab represents a strategic shift towards integrating its exoskeleton technology within established clinical workflows. This move addresses a key barrier to adoption – the complexity of evaluation and fitting – and positions Lifeward to capitalize on the growing demand for assistive robotics in rehabilitation. The partnership also highlights the increasing importance of specialized clinics in driving adoption of complex medical devices, a trend likely to accelerate as the market matures.

What we're watching

Adoption Rate
The success of this collaboration hinges on Lifeward's ability to convert evaluations into sales; a significant drop-off between trial and purchase would signal underlying issues with product suitability or pricing.
Reimbursement
Third-party payor coverage, particularly from CMS, remains a critical factor for widespread adoption; any changes in reimbursement policies could significantly impact Lifeward's revenue projections.
Competitive Landscape
The partnership may attract other exoskeleton manufacturers to seek similar collaborations, intensifying competition and potentially impacting Lifeward's market share and pricing power.
STELLAR CYBER INC.

Stellar Cyber's Partner Program Earns Top CRN Recognition

Event summary

  • Stellar Cyber's Infinity Partner Program received a 5-Star rating in the 2026 CRN Partner Program Guide.
  • The program launched in April 2025 and currently comprises over 300 MSSPs globally.
  • CRN assessed programs based on factors including training, support, marketing resources, and communication.
  • Stellar Cyber reports analyst productivity improvements of over 80% and false positive reductions of over 90% through its platform.

The big picture

Stellar Cyber's recognition highlights the increasing importance of robust partner programs for cybersecurity vendors, particularly those targeting the MSSP market. The 5-Star rating signals a strategic bet on the channel to expand market reach and deliver AI-powered security services, a trend accelerated by the growing complexity of cyber threats and the shortage of skilled security professionals. The program’s rapid growth to over 300 members in just over a year indicates a strong appetite for Stellar Cyber’s platform within the MSSP community.

What we're watching

Channel Dynamics
The continued reliance on MSSPs suggests Stellar Cyber's strategy is heavily dependent on the health and evolution of the channel, which could be impacted by broader economic shifts and vendor consolidation.
AI Adoption
The success of Stellar Cyber's 'Human Augmented Autonomous SOC' hinges on MSSPs' ability to effectively integrate and monetize AI-powered security solutions, a process that may encounter resistance or require significant upskilling.
Growth Sustainability
While the program has grown rapidly, maintaining partner engagement and satisfaction will be crucial to sustaining the 5-Star rating and preventing attrition within the Infinity Partner Program.
King Risk Partners, LLC

King Risk Partners Bolsters New York Presence with PRL Associates Acquisition

Event summary

  • King Risk Partners, the 51st largest insurance brokerage in the U.S., acquired PRL Associates, a New York-based insurance agency.
  • PRL Associates has operated for 15 years, providing personal and commercial insurance solutions across New York.
  • The acquisition expands King Risk Partners’ capabilities and presence within the Northeast region.
  • Scott Popilek, CEO of King Risk Partners, emphasized alignment in client service approaches.
  • Owners John Lavo and Steve Carr of PRL Associates highlighted the opportunity to broaden client solutions.

The big picture

King Risk Partners’ acquisition of PRL Associates is part of a broader trend of consolidation within the insurance brokerage industry, as mid-sized firms seek to gain scale and expand their geographic reach. The deal underscores the importance of regional specialization and client-centric service models in a competitive market. While King Risk Partners is currently the 51st largest brokerage, continued acquisitions like this will be necessary to significantly shift its position within the top tier.

What we're watching

Integration Risk
The success of this acquisition hinges on King Risk Partners’ ability to integrate PRL Associates’ operations and client relationships without disrupting service quality, a common challenge in brokerage acquisitions.
Client Retention
PRL Associates’ client-first approach is a key selling point, but retaining those clients under King Risk Partners’ ownership will be crucial to realizing the acquisition’s value.
Competitive Landscape
This acquisition signals increased consolidation within the New York insurance brokerage market, and further M&A activity is likely as larger players seek to expand their regional footprint.
Deloitte Touche Tohmatsu Limited

Deloitte, NVIDIA Expand Physical AI Partnership, Launch Shanghai Center

Event summary

  • Deloitte and NVIDIA are expanding their collaboration to deliver physical AI solutions leveraging NVIDIA Omniverse libraries.
  • Deloitte is establishing a global network of physical AI Centers of Excellence, with the first opening in Shanghai focused on manufacturing and industrial robotics.
  • Early implementations, including a project with Horse Powertrain, demonstrate reduced downtime and faster decision cycles through simulation-led testing and secure edge AI.
  • 58% of companies are currently using physical AI, with adoption projected to reach 80% within two years, according to Deloitte's State of AI in the Enterprise report.

The big picture

Deloitte's investment signals a deepening commitment to physical AI, a rapidly growing segment driven by the need for operational efficiency and resilience across industries. The partnership with NVIDIA leverages the latter’s full-stack AI platform to accelerate the deployment of intelligent systems, moving beyond experimental phases to full-scale production. This expansion aligns with the broader trend of enterprises integrating AI into physical processes to optimize performance and reduce risk.

What we're watching

Shanghai CoE
The success of the Shanghai Center of Excellence will be a key indicator of Deloitte’s ability to scale physical AI solutions and capture market share in the Chinese manufacturing sector.
Implementation Scale
Whether Deloitte can consistently deliver the promised operational improvements (reduced downtime, faster decisions) across diverse industries and clients will determine the long-term viability of this offering.
Competitive Landscape
The emergence of similar partnerships between other consulting firms and NVIDIA or competing AI platform providers could erode Deloitte's competitive advantage in the physical AI space.
UroGen Pharma Ltd.

UroGen Secures $250M Refinancing, Boosts Balance Sheet Flexibility

Event summary

  • UroGen Pharma secured a $250 million senior secured term loan from Pharmakon Advisors, replacing a previous $125 million facility.
  • The deal includes a $200 million tranche already funded and a $50 million tranche available until June 30, 2027.
  • The loan carries an 8.25% fixed interest rate and an extended amortization period until Q1 2030.
  • The refinancing provides UroGen with additional non-dilutive capital to support product lifecycle management and pipeline advancement.

The big picture

This refinancing demonstrates Pharmakon Advisors' continued conviction in UroGen's strategy, providing a significant capital injection at a favorable rate. The deal, totaling $250 million, underscores the growing trend of specialized credit funds like Pharmakon providing non-dilutive financing to biotech companies, particularly those with established commercial products and a pipeline of development candidates. The absence of financial covenants suggests a degree of confidence in UroGen's operational stability.

What we're watching

Capital Structure
The company's ability to draw down the remaining $50 million tranche will depend on progress against its stated goals for lifecycle management and pipeline advancement, revealing the true scope of its near-term investment plans.
Financial Performance
The impact of the lower interest rate on UroGen’s profitability will be a key indicator of the refinancing’s success, particularly given the company’s ongoing commercialization efforts.
Pipeline Progress
The allocation of the additional capital towards pipeline development will reveal the company’s strategic priorities and the potential for future revenue streams beyond its current product portfolio.
Aramark

Aramark Executives to Address Investors Amid Sector Scrutiny

Event summary

  • Aramark executives will participate in the UBS Global Consumer & Retail Investor Conference on March 11, 2026.
  • Jim Tarangelo, Executive Vice President and Chief Financial Officer, will lead a fireside chat and investor meetings at the UBS conference.
  • John Zillmer, CEO, will participate in a fireside chat and investor meetings at the BofA Securities Information & Business Services Investor Conference on March 12, 2026.
  • Live webcasts and replays of the fireside chats will be available on Aramark’s Investor Relations website.

The big picture

Aramark’s participation in these investor conferences suggests a proactive approach to managing market sentiment and addressing potential investor concerns. The food and facilities management sector faces ongoing headwinds from labor shortages, supply chain disruptions, and increased competition. These conferences provide a platform for management to articulate their strategy and address these challenges directly, which is particularly important given Aramark’s significant market capitalization and exposure to macroeconomic factors.

What we're watching

Growth Trajectory
How the company addresses investor concerns regarding organic growth in the face of inflationary pressures and potential contract renewals will be a key indicator of future performance.
Margin Pressure
Whether Aramark can sustain its current margins given rising labor costs and supply chain volatility will be closely monitored during the conference.
Contract Pipeline
The pace at which Aramark secures new, large-scale contracts will signal the effectiveness of its sales strategy and competitive positioning within the industry.
Cognition Therapeutics, Inc.

Cognition Therapeutics Prioritizes DLB Psychosis Path for Zervimesine

Event summary

  • Cognition Therapeutics plans to pursue a registrational path for zervimesine (CT1812) to treat dementia with Lewy bodies (DLB) psychosis, following a Type C meeting with the FDA in January 2026.
  • The Phase 2 ‘SHIMMER’ study demonstrated an 86% slowing of decline on the NPI-12 scale for zervimesine versus placebo in DLB patients.
  • The next clinical study will focus on neuropsychiatric and behavioral symptoms, with randomization to 100mg zervimesine or placebo daily.
  • DLB psychosis affects approximately 75% of DLB patients, a population with limited treatment options due to intolerance of traditional antipsychotics.
  • The NIH has provided approximately $30 million in grant funding (R01AG071643) to support the SHIMMER study.

The big picture

Cognition’s decision to prioritize DLB psychosis represents a strategic shift towards a niche market with significant unmet need, given the lack of approved therapies and the challenges associated with treating this patient population. This focus carries inherent risks, as regulatory pathways for rare disease treatments can be unpredictable, but also offers the potential for accelerated approval and market exclusivity if clinical trials are successful. The company’s reliance on NIH grant funding also introduces a dependency that investors should monitor.

What we're watching

Regulatory Risk
The FDA’s willingness to accept the Phase 2 data as sufficient for registration remains uncertain, and Cognition’s mid-year meeting will be critical in shaping the program’s design and timeline.
Clinical Efficacy
The observed benefit in the SHIMMER study must be replicated in a larger, pivotal trial to support regulatory approval and demonstrate a clinically meaningful impact on patient outcomes.
Market Adoption
Given the patient population's sensitivity to traditional antipsychotics, the successful launch of zervimesine will depend on demonstrating a superior safety profile and establishing clear guidelines for its use.
Trevi Therapeutics, Inc.

Trevi Therapeutics to Present at Key Investor and Rare Disease Forums

Event summary

  • Trevi Therapeutics executives Jennifer Good (President & CEO) and James Cassella (CDO) will participate in the Leerink Partners Healthcare Conference on March 11th.
  • Farrell Simon (CCO) will participate in the Access USA Rare Disease Summit on March 18th.
  • Haduvio™ (oral nalbuphine ER) is Trevi's investigational therapy targeting chronic cough in IPF, non-IPF ILD, and RCC.
  • The company estimates ~150,000 U.S. patients with IPF and ~228,000 with non-IPF ILD experience uncontrolled chronic cough.

The big picture

Trevi’s focus on chronic cough within IPF, non-IPF ILD, and RCC represents a strategic bet on a significant unmet need with limited existing therapeutic options. The company’s participation in these conferences underscores the importance of investor and specialist engagement in driving Haduvio’s development and potential commercialization, given the challenges inherent in rare disease drug development and the competitive landscape of respiratory therapies.

What we're watching

Investor Sentiment
The content of the Fireside Chat at Leerink will likely shape near-term investor perception of Haduvio’s development and commercial prospects, particularly given the competitive landscape in cough therapies.
Rare Disease Focus
Trevi’s participation in the Rare Disease Summit signals a deliberate effort to engage with specialists and build awareness, which will be crucial for navigating the complexities of rare disease drug launches.
Regulatory Pathway
The lack of scheduling by the U.S. Drug Enforcement Agency for nalbuphine provides a potential advantage, but the FDA’s eventual assessment of Haduvio’s safety and efficacy will be the ultimate determinant of its market access.
ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics Advances MSA Treatment, Phase 3 Trial Looms

Event summary

  • Alterity Therapeutics is advancing ATH434, an oral therapy, for Multiple System Atrophy (MSA), a rare neurodegenerative disease.
  • Phase 2 clinical trial data demonstrated statistically significant improvement on the modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I.
  • ATH434 has received Fast Track and Orphan Drug designations from the FDA and the European Commission.
  • Alterity plans to initiate a Phase 3 pivotal trial for ATH434 in MSA.

The big picture

MSA represents a significant unmet medical need, with no approved disease-modifying therapies currently available. Alterity's progress with ATH434 positions the company as a potential leader in this niche market, but the high-risk nature of drug development, particularly for rare diseases, means that success is far from guaranteed. The Phase 3 trial will be a pivotal moment for the company and the MSA patient community.

What we're watching

Clinical Efficacy
The success of the upcoming Phase 3 trial will be critical for establishing ATH434’s clinical benefit and securing regulatory approval, given the limited treatment options for MSA.
Regulatory Pathway
How the FDA and European Commission will weigh the Phase 2 data and biomarker responses in their assessment of ATH434’s efficacy will influence the trial design and approval timeline.
Commercialization
The ability of Alterity to secure partnerships or funding to support the commercial launch of ATH434, given the disease's rarity and the associated challenges in reaching patients, will be a key factor in long-term value creation.
Octochain Fintech Limited

On-Chain Gold Surges as Traditional Markets Close Amid Geopolitical Tensions

Event summary

  • On March 2, 2026, heightened U.S.-Iran tensions triggered rapid risk aversion and volatility in global markets.
  • Traditional gold markets were closed during this period, while on-chain gold assets (XAUT, PAXG) experienced significant price movement and trading volume increases.
  • The XAUT-USDT trading pair on Zoomex maintained liquidity and facilitated risk hedging for investors.
  • Zoomex reported stable operations and order execution during the period of extreme volatility.

The big picture

The event highlights a growing divergence between traditional financial market operating hours and the 24/7 nature of geopolitical risk. This is accelerating the adoption of blockchain-based assets, particularly gold, as a means of real-time hedging and price discovery. Zoomex's performance underscores the increasing importance of robust trading infrastructure in a world of frequent 'black swan' events, potentially reshaping the role of centralized exchanges.

What we're watching

Regulatory Response
Increased adoption of on-chain assets during market closures may draw regulatory scrutiny regarding price discovery and market integrity.
Platform Resilience
The ability of platforms like Zoomex to maintain stable execution under extreme volatility will be a key differentiator as geopolitical risks persist.
Adoption Rate
The pace at which institutional investors integrate on-chain gold into their risk management strategies will determine the long-term viability of this asset class.
Novo Nordisk

Ozempic Gains Expanded Canadian Approval, Broadening Cardiovascular Risk Mitigation

Event summary

  • Novo Nordisk’s Ozempic received Health Canada approval on March 2, 2026, expanding its indication to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes and established cardiovascular disease or chronic kidney disease.
  • The approval is based on pooled data from clinical trials SUSTAIN 6, PIONEER 6, FLOW, and SOUL, demonstrating a reduction in MACE risk.
  • Type 2 diabetes contributes to approximately 40% of heart attacks and 30% of strokes in Canada.
  • Ozempic was initially approved in Canada in 2018 for glycemic control in adults with type 2 diabetes.

The big picture

Novo Nordisk’s expanded Ozempic approval underscores the growing recognition of the interconnectedness of metabolic and cardiovascular health in diabetes management. This moves beyond glycemic control to address a significant unmet need, potentially capturing a larger share of the diabetes treatment market. The approval also highlights the increasing importance of cardiovascular outcomes trials in securing regulatory approvals for diabetes therapies, setting a precedent for future drug development.

What we're watching

Market Penetration
The speed of adoption of this expanded indication will depend on physician acceptance and patient access, potentially influenced by formulary decisions and reimbursement policies.
Competitive Landscape
Rivals will likely accelerate development of competing therapies targeting cardiovascular risk in diabetic patients, intensifying the competitive pressure on Novo Nordisk.
Clinical Data
Further real-world evidence regarding Ozempic’s impact on MACE and renal outcomes will be crucial for long-term market positioning and potential label expansions.
Precision BioSciences, Inc.

Precision BioSciences Collects $7.5M Milestone Payment for MS Gene Therapy

Event summary

  • Precision BioSciences received $7.5 million from TG Therapeutics related to the clinical progress of azer-cel, a gene therapy for multiple sclerosis.
  • The payment includes $5.25 million in cash and $2.25 million in Precision BioSciences common stock.
  • The milestone was triggered by progress in a Phase 1 clinical trial of azer-cel for progressive forms of multiple sclerosis.
  • Precision BioSciences anticipates the proceeds, combined with existing resources, will support operations through 2028.
  • The license agreement grants TG Therapeutics exclusive worldwide rights to develop and commercialize azer-cel for autoimmune diseases.

The big picture

This milestone payment provides Precision BioSciences with a near-term financial boost, but the company's long-term success hinges on the clinical validation of azer-cel and the broader adoption of its ARCUS platform. The deal highlights the growing trend of gene editing companies leveraging partnerships to accelerate development and share risk, particularly in areas like autoimmune disease where traditional therapies often fall short.

What we're watching

Clinical Efficacy
The Phase 1 trial data for azer-cel will be critical in determining the therapy’s potential and influencing future development decisions, and will likely dictate the timing and size of subsequent milestone payments.
Financial Stability
Precision BioSciences’ ability to extend its cash runway through 2028 will depend on continued milestone payments from TG Therapeutics and potentially other financing activities.
Partnering Strategy
The success of the TG Therapeutics partnership will shape Precision BioSciences’ approach to licensing its ARCUS platform and seeking external funding for its in vivo gene editing pipeline.
Upwind Security

Upwind Security Bets Big on APJ Amid Rising Cloud Security Costs

Event summary

  • Upwind Security is significantly expanding its presence in India and across Asia-Pacific and Japan (APJ), including local infrastructure and engineering teams.
  • The company has experienced 200% year-over-year growth in its global customer base and tripled its APJ workforce in the last three months.
  • Organizations in India face average cloud breach costs exceeding ₹220 million, while Australia estimates AUD $86 billion in economic impact from cyber incidents.
  • Upwind has added over 100 new partners in APJ, including strategic partnerships with NVIDIA, Microsoft Azure, and AWS.

The big picture

Upwind's aggressive expansion into APJ reflects the escalating cloud security risks and regulatory pressures facing enterprises in the region. The high breach costs and increasing complexity of hybrid/multi-cloud environments are driving demand for runtime security solutions. This move positions Upwind to capitalize on a rapidly growing market, but also exposes it to the challenges of scaling operations and competing with established players.

What we're watching

Regulatory Headwinds
The effectiveness of Upwind’s strategy will hinge on navigating increasingly stringent data residency and cybersecurity regulations like DPDA and PDPA across APJ.
Execution Risk
Rapid workforce expansion and infrastructure deployment pose execution risks; monitoring integration and operational efficiency will be crucial.
Competitive Landscape
The CNAPP space is becoming crowded; Upwind’s ability to differentiate through its runtime-first approach and partner ecosystem will determine its long-term success.
McFarlane Lake Mining Limited

McFarlane Lake Drilling Extends Mineralization Envelope at Juby Gold Project

Event summary

  • McFarlane Lake Mining's drilling at the Golden Lake Zone of the Juby Gold Project intersected 95.4 meters at 1.36 g/t gold, including higher-grade sections.
  • The discovery expands the mineralization envelope beyond the September 2025 mineral resource estimate.
  • Drilling at the 826 Zone has expanded the gold mineralization envelope to 300 meters along strike.
  • McFarlane plans to add a second diamond drill rig in mid-March 2026 to accelerate exploration.
  • The Juby Gold Project currently holds a mineral resource estimate of 1.01 million ounces of gold in the Indicated category and 3.17 million ounces in the Inferred category.

The big picture

McFarlane Lake's exploration success at Juby highlights the potential for resource expansion in the Abitibi Greenstone Belt, a historically prolific gold-producing region. The company's commitment to adding a second drill rig signals an acceleration of exploration activities, but also increases operational costs and requires careful management of resources. The expanded mineralization envelope, if confirmed, could significantly increase the project's overall value and attract further investment.

What we're watching

Resource Definition
The success of the additional drill program at Golden Lake will be critical in determining the extent of the expanded mineralization and its impact on future resource estimates.
Regulatory Approval
The progress of the environmental baseline study and subsequent application for a bulk sample extraction permit will dictate the timeline for potential near-term production.
Community Relations
Continued engagement and partnership with the First Nation communities holding territorial rights will be essential for maintaining operational license and avoiding delays.
REalloys Inc.

DLA Contract Fuels REalloys' Rare Earth Production Push

Event summary

  • REalloys’ Terves LLC subsidiary secured a contract from the Defense Logistics Agency (DLA) to scale Samarium (Sm) and Gadolinium (Gd) metal production.
  • The contract aims to establish a 300-ton-per-year modular production facility for these critical metals.
  • REalloys has filed a provisional patent for its zero-waste metallization process, potentially reducing production costs by up to 50%.
  • The DLA award follows REalloys’ acquisition of Terves LLC and Powdermet Inc. on March 31, 2025, through its PMT Critical Metals subsidiary.

The big picture

The DLA contract represents a significant shift towards onshoring critical rare earth metal production, driven by national security concerns and geopolitical instability. REalloys’ zero-waste process offers a potential cost advantage over traditional solvent extraction methods, but the company faces the challenge of scaling a novel technology to meet substantial demand. This move underscores the increasing strategic importance of rare earth metals for both defense and clean energy applications, and highlights the U.S. government’s commitment to securing domestic supply chains.

What we're watching

Execution Risk
Scaling the modular production facility to 300 tons per year will be a key challenge, and delays could impact the timeline for domestic supply chain establishment.
Competitive Landscape
While REalloys is positioned as a first-mover, other players may attempt to replicate its technology, potentially eroding its competitive advantage.
Government Dependence
REalloys’ reliance on DLA contracts for revenue creates a dependency on government procurement policies, which are subject to change.
Defense Metals Corp.

Rare Earth Prices Bolster Defense Metals' Wicheeda Project Economics

Event summary

  • Defense Metals' Wicheeda rare earth project economics are validated by a current NdPr price of US$128.75/kg, significantly higher than the US$110/kg floor price set by MP Materials in July 2025.
  • The project's Preliminary Feasibility Study (PFS) projects a pre-tax NPV of CAD $1.8 billion and a post-tax NPV of CAD $1.0 billion, with an IRR of ~24.6% and ~18.9%, respectively.
  • The British Columbia government has selected Wicheeda as one of four projects to receive support from the B.C. Critical Minerals Office (CMO).
  • Defense Metals was invited to participate in a Natural Resources Canada (NRCAN) roadshow in Europe, highlighting European interest in Western rare earth supply chains.

The big picture

Defense Metals' Wicheeda project benefits from a confluence of factors: rising NdPr prices driven by demand for permanent magnets in EVs and defense applications, government support for critical mineral development, and a desire for secure Western supply chains. The project's economics are heavily reliant on maintaining these favorable conditions, and the company's ability to navigate permitting and Indigenous relations will be key to its success. The current valuation reflects a significant premium based on these assumptions, making execution risk a critical factor.

What we're watching

Price Volatility
The current NdPr price surge may not be sustainable, and a correction could significantly impact the project's economic viability if the PFS assumptions prove overly optimistic.
Indigenous Relations
Continued engagement and alignment with Indigenous communities will be crucial for securing permits and maintaining social license to operate, potentially influencing the project timeline and costs.
Geopolitical Risk
The project's strategic importance to Western supply chains could expose it to geopolitical risks, including trade disputes or government intervention, which could impact offtake agreements and market access.
Aldebaran Resources Inc.

Rio Grande Resource Update Signals Exploration Upside for Centauri Minerals

Event summary

  • Aldebaran Resources and Centauri Minerals announced an updated mineral resource estimate for the Rio Grande gold-copper project in Salta, Argentina, increasing indicated and inferred resources.
  • The updated estimate includes 1.45 million ounces of gold, 384,000 tonnes of copper, and 12.7 million ounces of silver in indicated resources, and 1.55 million ounces of gold, 420,000 tonnes of copper, and 17.8 million ounces of silver in inferred resources.
  • The resource estimate indicates potential for deeper porphyry mineralization, with historical drilling intercepting 257.2 m of 1.20 g/t gold and 0.53% copper.
  • Centauri Minerals is planning a drill program in 2026 and aims to become a public company in the first half of 2026, following a spin-out from Aldebaran Resources.
  • Aldebaran will receive 40 million shares in Centauri as part of a share transfer agreement, with Aldebaran shareholders ultimately receiving Centauri shares upon Centauri's go-public event.

The big picture

The updated resource estimate for Rio Grande represents a significant opportunity for Centauri Minerals, particularly given the relative lack of exploration activity since 2012. The project’s location near the operating Lindero mine provides infrastructure advantages, but the success of Centauri’s exploration and development efforts will depend on effectively deploying modern exploration techniques and securing necessary permits. The spin-out structure allows Aldebaran to benefit from Centauri’s growth while focusing on its Altar project, but introduces complexities related to shareholder alignment and potential dilution.

What we're watching

Exploration Success
The success of Centauri’s planned 2026 drill program will be critical in validating the potential for deeper porphyry mineralization and expanding the resource base.
Spin-Out Execution
The timing and terms of Centauri’s planned public offering will determine the value realized by Aldebaran shareholders and the company’s access to capital.
Metallurgical Recovery
The ability to achieve the projected gold, copper, and silver recoveries through the planned heap leach and flotation processes will significantly impact the project’s economics.
NovaBridge Biosciences

NovaBridge to Detail Pipeline Progress at Leerink Conference

Event summary

  • NovaBridge Biosciences’ management will present at the Leerink Partners 2026 Global Healthcare Conference on March 11, 2026.
  • The presentation will be a fireside chat accessible via webcast starting at 8:00 AM ET.
  • NovaBridge’s pipeline is led by givastomig (Claudin 18.2 x 4-1BB bispecific antibody) and VIS-101 (VEGF-A and ANG-2 targeting biologic).
  • Givastomig recently announced positive topline results from a Phase 1b study for gastric cancer.

The big picture

NovaBridge’s participation in the Leerink conference signals an effort to maintain investor visibility and highlight progress in its pipeline. The company’s strategy of acquiring and accelerating assets, combined with its focus on bispecific antibodies, reflects a broader trend in the biotech sector towards more targeted and potentially more effective therapies. The success of givastomig, in particular, will be a key determinant of NovaBridge’s valuation and future growth prospects.

What we're watching

Clinical Data
The conference presentation will likely focus on the Phase 2 data for givastomig; investors should assess the clarity and robustness of these findings and their implications for potential regulatory pathways.
Partner Dynamics
The ongoing collaboration with ABL Bio on ragistomig warrants scrutiny; any shifts in the partnership structure or development timelines could impact NovaBridge’s overall pipeline strategy.
Market Positioning
Given the competitive landscape for VEGF-A/ANG-2 inhibitors, the presentation should clarify how VIS-101’s profile differentiates it and whether Visara’s commercialization strategy can secure market share.